Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase 2 5Phase 1/2 3Phase 3 1

Status

Completed 4Withdrawn 1

Sponsor Class

NIH 3OTHER 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 8Gastrointestinal 6Gynecologic 5Thoracic 3Genitourinary 2CNS 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × veliparib × Gynecologic × Clear all
NCT01266447 2019-08-08

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
27 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms

NCT01540565 2019-07-23

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 12 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01113957 2018-06-06

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

AbbVie

Phase 2 Completed
168 enrolled
Gynecologic

Ovarian Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

The University of Texas Health Science Center at San Antonio

Phase 2 Withdrawn
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01306032 2017-04-26

Phase II ABT-888 With Cyclophosphamide

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
124 enrolled 21 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡